-
1
-
-
45149131667
-
Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes
-
PID: 18539917
-
Gerstein HC, Miller ME, Byington RP et al (2008) Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358:2545–2559
-
(2008)
N Engl J Med
, vol.358
, pp. 2545-2559
-
-
Gerstein, H.C.1
Miller, M.E.2
Byington, R.P.3
-
2
-
-
45149133036
-
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
-
The ADVANCE Collaborative Group, Patel A, MacMahon S et al (2008) Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358:2560–2572
-
(2008)
N Engl J Med
, vol.358
, pp. 2560-2572
-
-
Patel, A.1
MacMahon, S.2
-
3
-
-
58149389215
-
Glucose control and vascular complications in veterans with type 2 diabetes
-
PID: 19092145
-
Duckworth W, Abraira C, Moritz T et al (2009) Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 360:129–139
-
(2009)
N Engl J Med
, vol.360
, pp. 129-139
-
-
Duckworth, W.1
Abraira, C.2
Moritz, T.3
-
4
-
-
84885997413
-
ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD)
-
PID: 23996285
-
Ryden L, Grant PJ, Anker SD et al (2013) ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J 34:3035–3087
-
(2013)
Eur Heart J
, vol.34
, pp. 3035-3087
-
-
Ryden, L.1
Grant, P.J.2
Anker, S.D.3
-
5
-
-
85041180129
-
How does empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of the EMPA-REG OUTCOME trial
-
PID: 29203583
-
Inzucchi SE, Zinman B, Fitchett D et al (2018) How does empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of the EMPA-REG OUTCOME trial. Diabetes Care 41:356–363
-
(2018)
Diabetes Care
, vol.41
, pp. 356-363
-
-
Inzucchi, S.E.1
Zinman, B.2
Fitchett, D.3
-
6
-
-
84883765959
-
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
-
PID: 23992601
-
Scirica BM, Bhatt DL, Braunwald E et al (2013) Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 369:1317–1326
-
(2013)
N Engl J Med
, vol.369
, pp. 1317-1326
-
-
Scirica, B.M.1
Bhatt, D.L.2
Braunwald, E.3
-
7
-
-
84937053742
-
Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes
-
PID: 26052984
-
Green JB, Bethel MA, Armstrong PW et al (2015) Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 373:232–242
-
(2015)
N Engl J Med
, vol.373
, pp. 232-242
-
-
Green, J.B.1
Bethel, M.A.2
Armstrong, P.W.3
-
8
-
-
84883745765
-
Alogliptin after acute coronary syndrome in patients with type 2 diabetes
-
PID: 23992602
-
White WB, Cannon CP, Heller SR et al (2013) Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 369:1327–1335
-
(2013)
N Engl J Med
, vol.369
, pp. 1327-1335
-
-
White, W.B.1
Cannon, C.P.2
Heller, S.R.3
-
9
-
-
84948740668
-
Lixisenatide in patients with type 2 diabetes and acute coronary syndrome
-
PID: 26630143
-
Pfeffer MA, Claggett B, Diaz R et al (2015) Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 373:2247–2257
-
(2015)
N Engl J Med
, vol.373
, pp. 2247-2257
-
-
Pfeffer, M.A.1
Claggett, B.2
Diaz, R.3
-
10
-
-
85030448557
-
Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes
-
PID: 28910237
-
Holman RR, Bethel MA, Mentz RJ et al (2017) Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med 377:1228–1239
-
(2017)
N Engl J Med
, vol.377
, pp. 1228-1239
-
-
Holman, R.R.1
Bethel, M.A.2
Mentz, R.J.3
-
11
-
-
84944800184
-
Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes
-
PID: 26378978
-
Zinman B, Wanner C, Lachin JM et al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373:2117–2128
-
(2015)
N Engl J Med
, vol.373
, pp. 2117-2128
-
-
Zinman, B.1
Wanner, C.2
Lachin, J.M.3
-
12
-
-
85023777061
-
Canagliflozin and cardiovascular and renal events in type 2 diabetes
-
PID: 28605608
-
Neal B, Perkovic V, Mahaffey KW et al (2017) Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377:644–657
-
(2017)
N Engl J Med
, vol.377
, pp. 644-657
-
-
Neal, B.1
Perkovic, V.2
Mahaffey, K.W.3
-
13
-
-
84978839381
-
Liraglutide and cardiovascular outcomes in type 2 diabetes
-
PID: 27295427
-
Marso SP, Daniels GH, Brown-Frandsen K et al (2016) Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375:311–322
-
(2016)
N Engl J Med
, vol.375
, pp. 311-322
-
-
Marso, S.P.1
Daniels, G.H.2
Brown-Frandsen, K.3
-
14
-
-
84994813253
-
Semaglutide and cardiovascular outcomes in patients with type 2 diabetes
-
PID: 27633186
-
Marso SP, Bain SC, Consoli A et al (2016) Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 375:1834–1844
-
(2016)
N Engl J Med
, vol.375
, pp. 1834-1844
-
-
Marso, S.P.1
Bain, S.C.2
Consoli, A.3
-
15
-
-
85042008156
-
DECLARE-TIMI 58: participants’ baseline characteristics
-
PID: 29322605
-
Raz I, Mosenzon O, Bonaca MP et al (2018) DECLARE-TIMI 58: participants’ baseline characteristics. Diabetes Obes Metab 20:1102–1110
-
(2018)
Diabetes Obes Metab
, vol.20
, pp. 1102-1110
-
-
Raz, I.1
Mosenzon, O.2
Bonaca, M.P.3
-
16
-
-
84975698839
-
Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME trial
-
PID: 26819227
-
Fitchett D, Zinman B, Wanner C et al (2016) Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME trial. Eur Heart J 37:1526–1534
-
(2016)
Eur Heart J
, vol.37
, pp. 1526-1534
-
-
Fitchett, D.1
Zinman, B.2
Wanner, C.3
-
17
-
-
85020460054
-
Diabetes mellitus and heart failure
-
PID: 28606342
-
Lehrke M, Marx N (2017) Diabetes mellitus and heart failure. Am J Cardiol 120:S37–S47
-
(2017)
Am J Cardiol
, vol.120
, pp. S37-S47
-
-
Lehrke, M.1
Marx, N.2
-
18
-
-
84898602820
-
Changes in diabetes-related complications in the United States. 1990-2010
-
PID: 24738668
-
Gregg EW, Li Y, Wang J et al (2014) Changes in diabetes-related complications in the United States. 1990-2010. N Engl J Med 370:1514–1523
-
(2014)
N Engl J Med
, vol.370
, pp. 1514-1523
-
-
Gregg, E.W.1
Li, Y.2
Wang, J.3
-
19
-
-
84955319328
-
Risk related to pre-diabetes mellitus and diabetes mellitus in heart failure with reduced ejection fraction: insights from prospective comparison of ARNI with ACEi to determine impact on global mortality and morbidity in heart failure trial
-
PID: 26754626
-
Kristensen SL, Preis D, Jhund PS et al (2016) Risk related to pre-diabetes mellitus and diabetes mellitus in heart failure with reduced ejection fraction: insights from prospective comparison of ARNI with ACEi to determine impact on global mortality and morbidity in heart failure trial. Circ Heart Fail 9:e002560
-
(2016)
Circ Heart Fail
, vol.9
-
-
Kristensen, S.L.1
Preis, D.2
Jhund, P.S.3
-
20
-
-
85055707998
-
Canagliflozin and heart failure in type 2 diabetes mellitus: Results from the CANVAS Program (Canagliflozin Cardiovascular Assessment Study)
-
Radholm K, Figtree G, Perkovic V et al (2018) Canagliflozin and heart failure in type 2 diabetes mellitus: results from the CANVAS Program (Canagliflozin Cardiovascular Assessment Study). Circulation 137. 10.1161/CIRCULATIONAHA.118.034222
-
(2018)
Circulation
, vol.137
-
-
Radholm, K.1
Figtree, G.2
Perkovic, V.3
-
21
-
-
85034093732
-
Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis
-
PID: 29024278
-
Hallow KM, Helmlinger G, Greasley PJ, McMurray JJV, Boulton DW (2018) Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis. Diabetes Obes Metab 20:479–487
-
(2018)
Diabetes Obes Metab
, vol.20
, pp. 479-487
-
-
Hallow, K.M.1
Helmlinger, G.2
Greasley, P.J.3
McMurray, J.J.V.4
Boulton, D.W.5
-
22
-
-
85030655315
-
The metabolodiuretic promise of sodium-dependent glucose cotransporter 2 inhibition: the search for the sweet spot in heart failure
-
PID: 28636701
-
Verma S, McMurray JJV, Cherney DZI (2017) The metabolodiuretic promise of sodium-dependent glucose cotransporter 2 inhibition: the search for the sweet spot in heart failure. JAMA Cardiol 2:939–940
-
(2017)
JAMA Cardiol
, vol.2
, pp. 939-940
-
-
Verma, S.1
McMurray, J.J.V.2
Cherney, D.Z.I.3
-
23
-
-
85031915334
-
Activation and inhibition of sodium-hydrogen exchanger is a mechanism that links the pathophysiology and treatment of diabetes mellitus with that of heart failure
-
PID: 29038209
-
Packer M (2017) Activation and inhibition of sodium-hydrogen exchanger is a mechanism that links the pathophysiology and treatment of diabetes mellitus with that of heart failure. Circulation 136:1548–1559
-
(2017)
Circulation
, vol.136
, pp. 1548-1559
-
-
Packer, M.1
-
24
-
-
84921374693
-
Functional role of glucose metabolism, osmotic stress, and sodium-glucose cotransporter isoform-mediated transport on Na+/H+ exchanger isoform 3 activity in the renal proximal tubule
-
PID: 24652792
-
Pessoa TD, Campos LC, Carraro-Lacroix L, Girardi AC, Malnic G (2014) Functional role of glucose metabolism, osmotic stress, and sodium-glucose cotransporter isoform-mediated transport on Na+/H+ exchanger isoform 3 activity in the renal proximal tubule. J Am Soc Nephrol 25:2028–2039
-
(2014)
J Am Soc Nephrol
, vol.25
, pp. 2028-2039
-
-
Pessoa, T.D.1
Campos, L.C.2
Carraro-Lacroix, L.3
Girardi, A.C.4
Malnic, G.5
-
25
-
-
84979895487
-
Empagliflozin and progression of kidney disease in type 2 diabetes
-
Wanner C, Inzucchi SE, Lachin JM et al (2016) Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 375:324–334
-
(2016)
N Engl J Med
, vol.375
, pp. 324-334
-
-
Wanner, C.1
Inzucchi, S.E.2
Lachin, J.M.3
-
26
-
-
85042792101
-
Empagliflozin and clinical outcomes in patients with type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney disease
-
PID: 28904068
-
Wanner C, Lachin JM, Inzucchi SE et al (2018) Empagliflozin and clinical outcomes in patients with type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney disease. Circulation 137:119–129
-
(2018)
Circulation
, vol.137
, pp. 119-129
-
-
Wanner, C.1
Lachin, J.M.2
Inzucchi, S.E.3
-
27
-
-
84980320178
-
Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications
-
PID: 27470878
-
Heerspink HJ, Perkins BA, Fitchett DH et al (2016) Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation 134:752–772
-
(2016)
Circulation
, vol.134
, pp. 752-772
-
-
Heerspink, H.J.1
Perkins, B.A.2
Fitchett, D.H.3
-
28
-
-
84996993010
-
Nephron protection in diabetic kidney disease
-
PID: 27959742
-
Anders H-J, Davis JM, Thurau K (2016) Nephron protection in diabetic kidney disease. N Engl J Med 375:2096–2098
-
(2016)
N Engl J Med
, vol.375
, pp. 2096-2098
-
-
Anders, H.-J.1
Davis, J.M.2
Thurau, K.3
-
29
-
-
85021254729
-
Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial
-
PID: 28666775
-
Cherney DZI, Zinman B, Inzucchi SE et al (2017) Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial. Lancet Diabetes Endocrinol 5:610–621
-
(2017)
Lancet Diabetes Endocrinol
, vol.5
, pp. 610-621
-
-
Cherney, D.Z.I.1
Zinman, B.2
Inzucchi, S.E.3
-
30
-
-
85020448574
-
Glomerular hyperfiltration in diabetes: mechanisms, clinical significance, and treatment
-
PID: 28143897
-
Tonneijck L, Muskiet MH, Smits MM et al (2017) Glomerular hyperfiltration in diabetes: mechanisms, clinical significance, and treatment. J Am Soc Nephrol 28:1023–1039
-
(2017)
J Am Soc Nephrol
, vol.28
, pp. 1023-1039
-
-
Tonneijck, L.1
Muskiet, M.H.2
Smits, M.M.3
-
31
-
-
84866359727
-
Glomerular hyperfiltration: a marker of early renal damage in pre-diabetes and pre-hypertension
-
PID: 22431709
-
Palatini P (2012) Glomerular hyperfiltration: a marker of early renal damage in pre-diabetes and pre-hypertension. Nephrol Dial Transplant 27:1708–1714
-
(2012)
Nephrol Dial Transplant
, vol.27
, pp. 1708-1714
-
-
Palatini, P.1
-
32
-
-
84929439992
-
Association between obesity and glomerular hyperfiltration: the confounding effect of smoking and sodium and protein intakes
-
PID: 25971845
-
Ogna A, Forni Ogna V, Bochud M et al (2016) Association between obesity and glomerular hyperfiltration: the confounding effect of smoking and sodium and protein intakes. Eur J Nutr 55:1089–1097
-
(2016)
Eur J Nutr
, vol.55
, pp. 1089-1097
-
-
Ogna, A.1
Forni Ogna, V.2
Bochud, M.3
-
33
-
-
84991083809
-
Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis
-
PID: 27212244
-
Targher G, Byrne CD, Lonardo A, Zoppini G, Barbui C (2016) Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis. J Hepatol 65:589–600
-
(2016)
J Hepatol
, vol.65
, pp. 589-600
-
-
Targher, G.1
Byrne, C.D.2
Lonardo, A.3
Zoppini, G.4
Barbui, C.5
-
34
-
-
84979220732
-
Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor) prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes
-
PID: 27462372
-
Jojima T, Tomotsune T, Jijima T, Akimoto K, Suzuki K, Aso Y (2016) Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor) prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes. Diabetol Metab Syndr 8:45
-
(2016)
Diabetol Metab Syndr
, vol.8
, pp. 45
-
-
Jojima, T.1
Tomotsune, T.2
Jijima, T.3
Akimoto, K.4
Suzuki, K.5
Aso, Y.6
-
35
-
-
85028766250
-
Effects of dapagliflozin on body composition and liver tests in patients with nonalcoholic steatohepatitis associated with type 2 diabetes mellitus: a prospective, open-label uncontrolled study
-
PID: 28912902
-
Tobita H, Sato S, Miyake T, Ishihara S, Kinoshita Y (2017) Effects of dapagliflozin on body composition and liver tests in patients with nonalcoholic steatohepatitis associated with type 2 diabetes mellitus: a prospective, open-label uncontrolled study. Curr Ther Res Clin Exp 87:13–19
-
(2017)
Curr Ther Res Clin Exp
, vol.87
, pp. 13-19
-
-
Tobita, H.1
Sato, S.2
Miyake, T.3
Ishihara, S.4
Kinoshita, Y.5
-
36
-
-
85008262665
-
Effect of sodium glucose cotransporter-2 inhibitor on liver function tests in Japanese patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus
-
PID: 27925353
-
Seko Y, Sumida Y, Tanaka S et al (2017) Effect of sodium glucose cotransporter-2 inhibitor on liver function tests in Japanese patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus. Hepatol Res 47:1072–1078
-
(2017)
Hepatol Res
, vol.47
, pp. 1072-1078
-
-
Seko, Y.1
Sumida, Y.2
Tanaka, S.3
-
37
-
-
84961615237
-
Ipragliflozin improves hepatic steatosis in obese mice and liver dysfunction in type 2 diabetic patients irrespective of body weight reduction
-
Komiya C, Tsuchiya K, Shibo K et al (2016) Ipragliflozin improves hepatic steatosis in obese mice and liver dysfunction in type 2 diabetic patients irrespective of body weight reduction. PLoS One 11:eo151511
-
(2016)
PLoS One
, vol.11
-
-
Komiya, C.1
Tsuchiya, K.2
Shibo, K.3
-
38
-
-
85016590472
-
Amelioration of fatty liver index in patients with type 2 diabetes on ipragliflozin: an association with glucose-lowering effect
-
PID: 27980239
-
Takase T, Nakamura A, Miyoshi H, Yamamoto C, Atsumi T (2017) Amelioration of fatty liver index in patients with type 2 diabetes on ipragliflozin: an association with glucose-lowering effect. Endocr J 64:363–367
-
(2017)
Endocr J
, vol.64
, pp. 363-367
-
-
Takase, T.1
Nakamura, A.2
Miyoshi, H.3
Yamamoto, C.4
Atsumi, T.5
-
39
-
-
85038094859
-
Current and future pharmacological therapies for NAFLD/NASH
-
PID: 29247356
-
Sumida Y, Yoneda M (2018) Current and future pharmacological therapies for NAFLD/NASH. J Gastroenterol 53:362–376
-
(2018)
J Gastroenterol
, vol.53
, pp. 362-376
-
-
Sumida, Y.1
Yoneda, M.2
|